[ad_1]
However, the situation in the media market is constantly changing: if you want to support quality business journalism and want to be part of the Portfolio community, subscribe to Portfolio Signature articles. Know more
The 75-year-old COVID-19 patient who was the first to receive the Hungarian-made remdesivir product at the institution was able to leave the epidemiological hospital established in the Department of Pulmonology at Semmelweis University, we wrote yesterday, citing a statement from the University by Semmelweis.
Now Béla Merkely, the rector of the university, also spoke about it, who also said that To date, no serious complications have been observed in patients treated at Semmelweis University who are being treated with the Hungarian product remdesivir.
He also mentioned that 26 patients received the drug at university., the IV product prevents the virus from multiplying so that the body can defeat the infection. The rector stated:
we are very optimistic about patients treated with remdesivir.
He said the drug is given to patients who need oxygen treatment and that timely medication can help with other therapeutic options, such as plasma treatment, corticosteroids.
Béla Merkely also spoke about the fact that in the case of patients infected with the virus, it is important not only to overcome the acute phase, but also to pay attention to the so-called residual symptoms caused by the infection. He added that the follow-up of patients treated with remdesivir lasts for one year.
Béla Merkely also mentioned that remdesivir has been certified by the US Food and Drug Administration (FDA) since October 22. He said that presumably the active ingredient in remdesivir will also receive a National Pharmacy and Food Health License for widespread use.
Hungarian patients were included in four-phase clinical trials investigating the drug’s safety and tolerability, Béla Merkely said.
Cover image source: MTI / Koszticsák Szilárd
[ad_2]
